Athersys, Inc. (ATHX) Said MultiStem Study Failed to Show Meaningful Benefit
Tweet Send to a Friend
Athersys, Inc. (NASDAQ: ATHX) announced interim results from the Phase 2 clinical study of the administration of Athersys' MultiStem® cell ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
